Pharmacological and genetic manipulation of kappa opioid receptors: Effects on cocaine- and pentylenetetrazol-induced convulsions and seizure kindling

Neuropharmacology

Volumn 52, Issue 3, 2007, Pages 895-903

  Kaminski, Rafal M ^a   Witkin, Jeffrey M ^a   Shippenberg, Toni S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cocaine; Convulsions; Kappa opioid receptor; Kindling; Knock out mice; Pentylenetetrazol; Seizure

Indexed keywords

COCAINE; KAPPA OPIATE RECEPTOR; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NORBINALTORPHIMINE; PENTETRAZOLE;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CONVULSION; DATA ANALYSIS; DOSE RESPONSE; GENETIC MANIPULATION; KINDLING; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE; SEIZURE THRESHOLD; SWISS WEBSTER MOUSE; WILD TYPE;

ANALGESICS; ANIMALS; BEHAVIOR, ANIMAL; BENZENEACETAMIDES; COCAINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NALTREXONE; NARCOTIC ANTAGONISTS; PENTYLENETETRAZOLE; PYRROLIDINES; RECEPTORS, OPIOID, KAPPA; SEIZURES;

EID: 33846869290     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.10.007     Document Type: Article

References (66)

1. Albertson T.E., Joy R.M., and Stark L.G. Modification of kindled amygdaloid seizures by opiate agonists and antagonists. Journal of Pharmacology and Experimental Therapeutics 228 (1984) 620-627
2. Bausch S.B., Esteb T.M., Terman G.W., and Chavkin C. Administered and endogenously released kappa opioids decrease pilocarpine-induced seizures and seizure-induced histopathology. Journal of Pharmacology and Experimental Therapeutics 284 (1998) 1147-1155
3. Becker A., Braun H., Schroder H., Grecksch G., and Hollt V. Effects of enadoline on the development of pentylenetetrazol kindling, learning performance, and hippocampal morphology. Brain Research 823 (1999) 191-197
4. Braida D., Paladini E., Gori E., and Sala M. Naltrexone, naltrindole, and CTOP block cocaine-induced sensitization to seizures and death. Peptides 18 (1997) 1189-1195
5. Broadbear J.H., Negus S.S., Butelman E.R., de Costa B.R., and Woods J.H. Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay. Psychopharmacology (Berlin) 115 (1994) 311-319
6. Butelman E.R., Ko M.C., Sobczyk-Kojiro K., Mosberg H.I., Van Bemmel B., Zernig G., and Woods J.H. Kappa-Opioid receptor binding populations in rhesus monkey brain: relationship to an assay of thermal antinociception. Journal of Pharmacology and Experimental Therapeutics 285 (1998) 595-601
7. Camacho Ochoa M., Jackson T.A., Aaron C.S., Lahti R.A., Strain G.M., and Von Voigtlander P.F. Antagonism of kainic acid lesions in the mouse hippocampus by U-54494A and U-50488H. Life Sciences 51 (1992) 1135-1143
8. Chavkin C., James I.F., and Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 215 (1982) 413-415
9. Chefer V.I., Moron J.A., Hope B., Rea W., and Shippenberg T.S. Kappa-opioid receptor activation prevents alterations in mesocortical dopamine neurotransmission that occur during abstinence from cocaine. Neuroscience 101 (2000) 619-627
10. Chefer V.I., Czyzyk T., Bolan E.A., Moron J., Pintar J.E., and Shippenberg T.S. Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine. Journal of Neuroscience 25 (2005) 5029-5037
11. Cowan A., Lewis J.W., and MacFarlane I.R. Agonist and antagonist properties of buprenorphine: a new antinociceptive agent. British Journal of Pharmacology 60 (1977) 537-545
12. Derlet R.W., and Albertson T.E. Emergency department presentation of cocaine intoxication. Annals of Emergency Medicine 18 (1989) 182-186
13. Derlet R.W., Tseng C.C., Tharratt R.S., and Albertson T.E. The effect of morphine and naloxone on cocaine toxicity. American Journal of The Medical Sciences 303 (1992) 165-169
14. Dhuna A., Pascual-Leone A., Langendorf F., and Anderson D.C. Epileptogenic properties of cocaine in humans. Neurotoxicology 12 (1991) 621-626
15. Dhuna A., Pascual-Leone A., and Langendorf F. Chronic, habitual cocaine abuse and kindling-induced epilepsy: a case report. Epilepsia 32 (1991) 890-894
16. Fischer W., Bodewei R., VonVoigtlander P.F., and Muller M. Anticonvulsant and related effects of U-54494A in various seizure tests. Journal of Pharmacology and Experimental Therapeutics 267 (1993) 163-170
17. Gasior M., Carter R.B., Goldberg S.R., and Witkin J.M. Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam. Journal of Pharmacology and Experimental Therapeutics 282 (1997) 543-553
18. Gasior M., Beekman M., Carter R.B., Goldberg S.R., and Witkin J.M. Antiepileptogenic effects of the novel synthetic neuroactive steroid, ganaxolone, against pentylenetetrazol-induced kindled seizures: Comparison with diazepam and valproate. Drug Development Research 44 (1998) 21-33
19. Heidbreder C.A., Goldberg S.R., and Shippenberg T.S. The kappa-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat. Brain Research 616 (1993) 335-338
20. Heidbreder C.A., Babovic-Vuksanovic D., Shoaib M., and Shippenberg T.S. Development of behavioral sensitization to cocaine: influence of kappa opioid receptor agonists. Journal of Pharmacology and Experimental Therapeutics 275 (1995) 150-163
21. Hough L.B., Nalwalk J.W., Chen Y., Schuller A., Zhu Y., Zhang J., Menge W.M., Leurs R., Timmerman H., and Pintar J.E. Improgan, a cimetidine analog, induces morphine-like antinociception in opioid receptor-knock-out mice. Brain Research 880 (2000) 102-108
22. Huang R.Q., Bell-Horner C.L., Dibas M.I., Covey D.F., Drewe J.A., and Dillon G.H. Pentylenetetrazole-induced inhibition of recombinant gamma-aminobutyric acid type A (GABA(A)) receptors: mechanism and site of action. Journal of Pharmacology and Experimental Therapeutics 298 (2001) 986-995
23. Kaminski R.M., Gasior M., Carter R.B., and Witkin J.M. Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice. European Journal of Pharmacology 474 (2003) 217-222
24. Kaminski R.M., Shippenberg T.S., Witkin J.M., and Rocha B.A. Genetic deletion of the norepinephrine transporter decreases vulnerability to seizures. Neuroscience Letters 382 (2005) 51-55
25. Kantak K.M., Riberdy A., and Spealman R.D. Cocaine-opioid interactions in groups of rats trained to discriminate different doses of cocaine. Psychopharmacology (Berlin) 147 (1999) 257-265
26. Karler R., Calder L.D., Chaudhry I.A., and Turkanis S.A. Blockade of "reverse tolerance" to cocaine and amphetamine by MK-801. Life Sciences 45 (1989) 599-606
27. Koppel B.S., Samkoff L., and Daras M. Relation of cocaine use to seizures and epilepsy. Epilepsia 37 (1996) 875-878
28. Lahti R.A., Mickelson M.M., McCall J.M., and Von Voigtlander P.F. [3H]U-69593 a highly selective ligand for the opioid kappa receptor. European Journal of Pharmacology 109 (1985) 281-284
29. Lason W. Neurochemical and pharmacological aspects of cocaine-induced seizures. Polish Journal of Pharmacology 53 (2001) 57-60
30. Leander J.D. Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology 26 (1987) 1445-1447
31. Litchfield J.T., and Wilcoxon F. A simplified method of evaluating dose-effect experiments. Journal of Pharmacology and Experimental Therapeutics 96 (1949) 99-113
32. Löscher W., Honack D., Fassbender C.P., and Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Research 8 (1991) 171-189
33. Madamba S.G., Schweitzer P., and Siggins G.R. Dynorphin selectively augments the M-current in hippocampal CA1 neurons by an opiate receptor mechanism. Journal of Neurophysiology 82 (1999) 1768-1775
34. Manocha A., Mediratta P.K., and Sharma K.K. Studies on the anticonvulsant effect of U50488H on maximal electroshock seizure in mice. Pharmacology Biochemistry and Behavior 76 (2003) 111-117
35. Mazarati A., and Wasterlain C.G. Anticonvulsant effects of four neuropeptides in the rat hippocampus during self-sustaining status epilepticus. Neuroscience Letters 331 (2002) 123-127
36. Mello N.K., and Negus S.S. Interactions between kappa opioid agonists and cocaine. Preclinical studies. Annals of the New York Academy of Sciences 909 (2000) 104-132
37. Miller K.A., Witkin J.M., Ungard J.T., and Gasior M. Pharmacological and behavioral characterization of cocaine-kindled seizures in mice. Psychopharmacology (Berlin) 148 (2000) 74-82
38. Patterson A.B., Gordon F.J., and Holtzman S.G. Naltrindole, a selective delta-opioid receptor antagonist, potentiates the lethal effects of cocaine by a central mechanism of action. European Journal of Pharmacology 333 (1997) 47-54
39. Przewlocka B., Stala L., Lason W., and Przewlocki R. The effect of various opiate receptor agonists on the seizure threshold in the rat. Is dynorphin an endogenous anticonvulsant?. Life Sciences 33 (Suppl. 1) (1983) 595-598
40. Przewlocka B., Machelska H., and Lason W. Kappa opioid receptor agonists inhibit the pilocarpine-induced seizures and toxicity in the mouse. European Neuropsychopharmacology 4 (1994) 527-533
41. Rawls S.M., and McGinty J.F. Kappa receptor activation attenuates L-trans-pyrrolidine-2,4-dicarboxylic acid-evoked glutamate levels in the striatum. Journal of Neurochemistry 70 (1998) 626-634
42. Samoriski G.M., Piekut D.T., and Applegate C.D. Differential spatial patterns of Fos induction following generalized clonic and generalized tonic seizures. Experimental Neurology 143 (1997) 255-268
43. Schenk S., Partridge B., and Shippenberg T.S. U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology (Berlin) 144 (1999) 339-346
44. Schenk S., Partridge B., and Shippenberg T.S. Effects of the kappa-opioid receptor agonist, U69593, on the development of sensitization and on the maintenance of cocaine self-administration. Neuropsychopharmacology 24 (2001) 441-450
45. Shippenberg T.S., LeFevour A., and Heidbreder C. kappa-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine. Journal of Pharmacology and Experimental Therapeutics 276 (1996) 545-554
46. Shippenberg T.S., Chefer V.I., Zapata A., and Heidbreder C.A. Modulation of the behavioral and neurochemical effects of psychostimulants by kappa-opioid receptor systems. Annals of the New York Academy of Sciences 937 (2001) 50-73
47. Simonato M., and Romualdi P. Dynorphin and epilepsy. Progress in Neurobiology 50 (1996) 557-583
48. Snyder-Keller A., and Keller Jr. R.W. Spatiotemporal analysis of Fos expression associated with cocaine- and PTZ-induced seizures in prenatally cocaine-treated rats. Experimental Neurology 170 (2001) 109-120
49. Solbrig M.V., and Koob G.F. Epilepsy, CNS viral injury and dynorphin. Trends in Pharmacological Sciences 25 (2004) 98-104
50. Solbrig M.V., Adrian R., Baratta J., Lauterborn J.C., and Koob G.F. Kappa opioid control of seizures produced by a virus in an animal model. Brain 129 (2006) 642-654
51. Spealman R.D., and Bergman J. Modulation of the discriminative stimulus effects of cocaine by mu and kappa opioids. Journal of Pharmacology and Experimental Therapeutics 261 (1992) 607-615
52. Spealman R.D., and Bergman J. Opioid modulation of the discriminative stimulus effects of cocaine: comparison of micro, kappa and delta agonists in squirrel monkeys discriminating low doses of cocaine. Behavioral Pharmacology 5 (1994) 21-31
53. Tallarida R.J., and Murray R.B. Manual of Pharmacologic Calculations with Computer Programs (1987), Springer, New York
54. Thompson A.C., Zapata A., Justice J.B., Vaughan R.A., Sharpe L.G., and Shippenberg T.S. Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine. Journal of Neuroscience 20 (2000) 9333-9340
55. Tortella F.C., Robles L., Echevarria E., Hunter J.C., and Hughes J. PD117302, a selective non-peptide opioid kappa agonist, protects against NMDA and maximal electroshock convulsions in rats. Life Sciences 46 (1990) 1135-1143
56. Vanderschuren L.J., Schoffelmeer A.N., Wardeh G., and De Vries T.J. Dissociable effects of the kappa-opioid receptor agonists bremazocine, U69593, and U50488H on locomotor activity and long-term behavioral sensitization induced by amphetamine and cocaine. Psychopharmacology (Berlin) 150 (2000) 35-44
57. VonVoigtlander P.F., Hall E.D., Ochoa M.C., Lewis R.A., and Triezenberg H.J. U-54494A: a unique anticonvulsant related to kappa opioid agonists. Journal of Pharmacology and Experimental Therapeutics 243 (1987) 542-547
58. Wagner J.J., Caudle R.M., and Chavkin C. Kappa-opioids decrease excitatory transmission in the dentate gyrus of the guinea pig hippocampus. Journal of Neuroscience 12 (1992) 132-141
59. Walker J.M., Bowen W.D., Walker F.O., Matsumoto R.R., De Costa B., and Rice K.C. Sigma receptors: biology and function. Pharmacological Reviews 42 (1990) 355-402
60. Wasterlain C.G., Mazarati A.M., Naylor D., Niquet J., Liu H., Suchomelova L., Baldwin R., Katsumori H., Shirasaka Y., Shin D., and Sankar R. Short-term plasticity of hippocampal neuropeptides and neuronal circuitry in experimental status epilepticus. Epilepsia 43 (Suppl. 5) (2002) 20-29
61. Weiss S.R., Post R.M., Costello M., Nutt D.J., and Tandeciarz S. Carbamazepine retards the development of cocaine-kindled seizures but not sensitization to cocaine-induced hyperactivity. Neuropsychopharmacology 3 (1990) 273-281
62. Witkin J.M., Goldberg S.R., and Katz J.L. Lethal effects of cocaine are reduced by the dopamine-1 receptor antagonist SCH 23390 but not by haloperidol. Life Sciences 44 (1989) 1285-1291
63. Witkin J.M., Johnson R.E., Jaffe J.H., Goldberg S.R., Grayson N.A., Rice K.C., and Katz J.L. The partial opioid agonist, buprenorphine, protects against lethal effects of cocaine. Drug and Alcohol Dependence 27 (1991) 177-184
64. Witkin J.M., Gasior M., Heifets B., and Tortella F.C. Anticonvulsant efficacy of N-methyl-d-aspartate antagonists against convulsions induced by cocaine. Journal of Pharmacology and Experimental Therapeutics 289 (1999) 703-711
65. Witkin J.M., Newman A.H., Nowak G., and Katz J.L. Role of dopamine D1 receptors in the lethal effects of cocaine and a quaternary methiodide analog. Journal of Pharmacology and Experimental Therapeutics 267 (1993) 266-274
66. Yajima Y., Narita M., Takahashi-Nakano Y., Misawa M., Nagase H., Mizoguchi H., Tseng L.F., and Suzuki T. Effects of differential modulation of mu-, delta- and kappa-opioid systems on bicuculline-induced convulsions in the mouse. Brain Research 862 (2000) 120-126